Neumora Therapeutics, INC Form 4 insider transactions

Neumora Therapeutics, Inc. (NMRA) has repriced stock options for its CEO and Chairman, Paul L. Berns, and other key personnel, significantly lowering the exercise price from $1.69 to $0.72 per share.

Neumora Therapeutics, Inc. (NMRA) announced that its stockholders approved the repricing of stock options for Director Maykin Ho and other key personnel, significantly lowering the exercise price to $0.72 per share.

A director at Neumora Therapeutics, Inc. has received repriced stock options and a new option grant, approved by shareholders, adjusting exercise prices to incentivize future performance.

Neumora Therapeutics, Inc. (NMRA) has repriced stock options for its President, Joshua Pinto, significantly lowering the exercise price from $1.69 to $0.72 per share, following stockholder approval on May 28, 2025.

Joshua Pinto, President of Neumora Therapeutics, Inc., transferred 13,202 shares of common stock to a family limited liability company, maintaining investment control.

Paul L. Berns, a director and officer of Neumora Therapeutics, sold shares of common stock on February 18, 2025, to cover withholding tax obligations related to vesting restricted stock units.

Michael Milligan, CFO of Neumora Therapeutics, sold 1,978 shares of common stock on February 18, 2025, to cover withholding obligations related to vesting restricted stock units.

Daljit Singh Aurora, Chief Strategy Officer of Neumora Therapeutics, sold shares of common stock on February 18, 2025, to satisfy tax withholding obligations related to vesting restricted stock units.

Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold 5,614 shares of common stock on February 18, 2025, to cover withholding obligations related to vesting restricted stock units.

Joshua Pinto, President of Neumora Therapeutics, sold 8,048 shares of common stock on February 18, 2025, to satisfy withholding obligations related to vesting restricted stock units.

Paul L. Berns, a director and officer of Neumora Therapeutics, received an option repricing and new stock options on February 13, 2025, subject to stockholder approval.

Robert A. Lenz, Head of R&D at Neumora Therapeutics, repriced stock options on February 13, 2025, pending stockholder approval.

Maykin Ho, a director at Neumora Therapeutics, reported the repricing of stock options on February 13, 2025, subject to stockholder approval.

Daljit Singh Aurora, Chief Operating and Development Officer of Neumora Therapeutics, reports the repricing of stock options and acquisition of new options at a lower exercise price, according to a Form 4 filing.

Director David Piacquad reports repricing of stock options in Neumora Therapeutics, contingent on stockholder approval.

Director Matthew K. Fust reports changes in beneficial ownership of Neumora Therapeutics stock due to stock option repricing approved by the board.

Kristina Burow, a director at Neumora Therapeutics, Inc., reports changes in beneficial ownership due to the repricing of stock options.

Jason Duncan, Chief Legal and Administrative Officer of Neumora Therapeutics, reports the grant of new stock options and the repricing of existing options.

Joshua Pinto, President of Neumora Therapeutics, reports the repricing and grant of stock options, subject to stockholder approval, according to a Form 4 filing.

Michael Lee Milligan, CFO of Neumora Therapeutics, received new stock options and had existing stock options repriced at $1.69 per share on February 13, 2025, subject to stockholder approval.

Director Alaa Halawa receives repriced stock options from Neumora Therapeutics, pending stockholder approval, as disclosed in a Form 4 filing.

Paul L. Berns, a director at Neumora Therapeutics, transferred shares of common stock to family trusts on December 27, 2024.

Director Matthew K. Fust of Neumora Therapeutics, Inc. reports multiple transactions involving common stock, including acquisitions through option exercises and sales under a 10b5-1 trading plan.

Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of NMRA common stock on October 9 and 10, 2024, under a pre-arranged 10b5-1 trading plan.

Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of common stock on September 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of common stock on September 12, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Daljit Singh Aurora, Chief Strategy Officer of Neumora Therapeutics, reports the transfer of fully vested stock options to the Aurora Family Trust.

Neumora Therapeutics' CFO, Joshua Pinto, sold 15,693 shares of common stock at a weighted average price of $11.394 per share on August 27, 2024, under a pre-arranged 10b5-1 trading plan.

Neumora Therapeutics' CFO, Joshua Pinto, executed multiple sales of common stock between August 22 and August 26, 2024, under a pre-arranged 10b5-1 trading plan.

Joshua Pinto, CFO of Neumora Therapeutics, reports a transfer of shares to a family limited liability company and subsequent transfer of membership interests to a trust for estate planning purposes.